Mallinckrodt drug shows benefit in rare liver, kidney disease
The drugmaker reported top-line data from its Phase III study of terlipressin in hepatorenal syndrome type 1, or HSR-1, a disease with no drug treatment available in the U.S. or Canada that affects 30,000-40,000 people per year.